The safety and tolerability of an HIV-1 DNA prime–protein boost vaccine (DP6-001) in healthy adult volunteers
- 25 June 2008
- journal article
- clinical trial
- Published by Elsevier BV in Vaccine
- Vol. 26 (35), 4420-4424
- https://doi.org/10.1016/j.vaccine.2008.05.090
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesThe Journal of Experimental Medicine, 2008
- Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime–protein boost HIV-1 vaccine in healthy human volunteersVaccine, 2008
- Safety and Immunogenicity of a Gag-Pol Candidate HIV-1 DNA Vaccine Administered by a Needle-Free Device in HIV-1-Seronegative SubjectsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 DNA Candidate VaccineThe Journal of Infectious Diseases, 2006
- Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adultsVaccine, 2005
- Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes RecognizedJournal of Virology, 2003
- QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humansVaccine, 2001
- Delayed hypersensitivity, immune deviation, antigen processing and T-cell subset selection in syphilis pathogenesis and vaccine designImmunology Today, 1993
- Target Platelet Antigen in Homosexual Men with Immune ThrombocytopeniaNew England Journal of Medicine, 1985
- On the Mechanism of Thrombocytopenic Purpura in Sexually Active Homosexual MenNew England Journal of Medicine, 1984